Between 2007 and 2019, over 168 studies of analytical performance were published, with no clinical interferences found for StatStrip Glucose. These studies were conducted at some of the most prestigious hospitals and diabetes centers in the world, and prove that Nova Biomedical’s StatStrip glucose sensor technology dramatically improves accuracy by eliminating hematocrit and other interferences. Study sites include: Mayo Clinic College of Medicine, Rochester, Minnesota; The Johns Hopkins University School of Medicine, Baltimore, Maryland; University of Toronto Sunnybrook Health Sciences Centre, Toronto, Canada; Addenbrook’s Hospital, Cambridge University Hospitals, United Kingdom; University Hospital of Wales, Cardiff, Wales; Isala Klinieken, Zwolle, Netherlands; Saint-Pierre Hospital, Brussels, Belgium; and Saitama Medical University, Saitama, Japan.
To download a bibliography of publications click here